Geron Corporation

We are a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF), and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under the terms of an exclusive worldwide collaboration and license agreement.The role of telomerase and the potential implications for cancer have been a focus of Geron since our founding. The discovery and early development of imetelstat, our sole product candidate, was based on our core expertise in telomerase and telomere biology. Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using our proprietary nucleic acid chemistry.

Bank Name Geron Corporation
Stock Exchange NASDAQ
Symbol GERN
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region America
Chairman
CEO Dr. John A. Scarlett
Employees 15
Website www.geron.com
Registered Year 1990

UpdateContent
UpdateContent
UpdateContent